Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
Radiotherapy for Oligometastatic Prostate Cancer
|5||Active, not recruiting||
Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
† Study has passed its completion date and status has not been verified in more than two years.